March R, Cheeseman K, Doherty M
Research and Development Genetics, AstraZeneca, Mereside, Alderley Park, Macclesfield, Cheshire, SK10 4TG, UK.
Pharmacogenomics. 2001 Nov;2(4):317-27. doi: 10.1517/14622416.2.4.317.
The overall objective of pharmacogenetics is to determine the genetic basis of variability in drug efficacy and safety, and to use this information to benefit the patient. Genetics can be used to develop drugs that are suitable for the majority of patients and to help identify those patients for whom a certain drug may not be the most appropriate. This review will cover some background to pharmacogenetics and various issues including confidentiality, data protection, coding of samples and genetic data, informed consent, and drug development guidelines. International, national and regional variation in the legal and regulatory basis for pharmacogenetics presents challenges for researchers attempting to increase scientific understanding in the field. Examples of national and international regulations and guidelines will be given. It is clear that pharmacogenetics today is a long way from the 'personalised medicine' advocated by some individuals in recent years. The aim of pharmacogenetic research should always be to make sure that patients have the best treatment available and that patients are not exposed to drugs to which they are genetically unable to respond. This vision must continue to inspire researchers and regulators who are working together to make it a widespread reality.
药物遗传学的总体目标是确定药物疗效和安全性变异性的遗传基础,并利用这些信息使患者受益。遗传学可用于开发适用于大多数患者的药物,并有助于识别某些药物可能并非最合适的患者。本综述将涵盖药物遗传学的一些背景知识以及包括保密、数据保护、样本和遗传数据编码、知情同意和药物开发指南等各种问题。药物遗传学在法律和监管基础方面的国际、国家和地区差异给试图增进该领域科学认识的研究人员带来了挑战。将给出国家和国际法规及指南的示例。很明显,如今的药物遗传学距离近年来一些人所倡导的“个性化医疗”还有很长的路要走。药物遗传学研究的目标应该始终是确保患者获得最佳可用治疗,并且患者不会接触到他们在基因上无法产生反应的药物。这一愿景必须继续激励共同努力使其广泛成为现实的研究人员和监管者。